AIS Biotech, founded in 2023 and based in the Grenoble/Isère region, is developing GlycoFlu, a nasal antiviral composed of synthetic oligosaccharides that mimic cellular sugars to trap Influenza viruses before cell entry. The company leverages 25 years of academic research and is currently in preclinical development of its lead candidate. AIS also plans to industrialize a bioproduction platform for complex sugars to target other infectious diseases. The startup has four employees and intends to hire three more in the coming months to support R&D. The recent financing will accelerate preclinical work on GlycoFlu and broaden research on additional therapeutic targets. Company leadership (the three founders/executives) remain majority shareholders after the round.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2025